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Original ArticleCluster Analysis on Longitudinal Data of Patients
with Adult-Onset AsthmaPinja Ilmarinen, PhDa, Leena E. Tuomisto, MD, PhDa, Onni Niemelä, MD, PhDb,c, Minna Tommola, MDa,
Jussi Haanpää, MScd, and Hannu Kankaanranta, MD, PhDa,e Seinäjoki and Tampere, FinlandWhat is already known about this topic?Many phenotypes of asthma have been identiﬁed in previous cluster analyses,
mostly on the basis of cross-sectional data with limited inclusion of patients. Some studies have provided short-term 1- to
3-year prognosis for the phenotypes.
What does this article add to our knowledge? This is the ﬁrst study that reports long-term 12-year prognosis for clusters
of adult-onset asthma starting from diagnosis. We report different disease prognoses for smoking, obesity-related, female,
atopic, and nonrhinitic asthma.
How does this study impact current management guidelines? Information on long-term outcome of asthma can be
used to inform and motivate patients. We show the poorest outcome and the most unmet needs in the therapy of smoking
and obesity-related asthma, suggesting need for special guidance.BACKGROUND: Previous cluster analyses on asthma are based
on cross-sectional data.
OBJECTIVE: To identify phenotypes of adult-onset asthma by
using data from baseline (diagnostic) and 12-year follow-up
visits.
METHODS: The Seinäjoki Adult Asthma Study is a 12-year
follow-up study of patients with new-onset adult asthma.
K-means cluster analysis was performed by using variables from
baseline and follow-up visits on 171 patients to identify
phenotypes.
RESULTS: Five clusters were identiﬁed. Patients in cluster
1 (n[ 38) were predominantly nonatopic males with moderate
smoking history at baseline. At follow-up, 40% of these patients
had developed persistent obstruction but the number of patients
with uncontrolled asthma (5%) and rhinitis (10%) was the
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Early-onset
Adult- or late-onset asthma has been suggested to be a
distinctive phenotype of asthma.1,2 Patients with adult-onset
asthma have lesser allergic processes, lower lung function
despite shorter duration of disease, and more often a pronounced
eosinophilic inﬂammation without evidence of TH2eassociated
inﬂammation when compared with patients with childhood-
onset asthma.1 These ﬁndings suggest that adult-onset asthma
is more heterogeneous when compared with childhood-onset
asthma. In previous studies, subphenotypes of adult-onset
asthma such as eosinophil-predominant, mild to moderate
well-controlled, obesity-related, smoking, and severe obstructive
asthma have been proposed.3,4
To identify phenotypes of asthma, unsupervised hierarchical
cluster analyses have been carried out. However, the cluster an-
alyses have mostly been based on cross-sectional data on patients
with mixed duration of asthma.2,4-6 Asthma is known as a disease
with a high degree of variability, making one time point a fragile
basis for cluster analysis. Furthermore, no information on the
diagnostic phase has been included in the previous analyses. In
addition, many previous analyses have clustered patients with
severe asthma,7,8 leaving milder forms with less attention. Some
studies have involved short follow-ups (1-3 years).6,7,9,10 In a
previous prospective longitudinal analysis of severe asthma, the
clusters did not show cluster-speciﬁc disease courses regarding
outcome of asthma, suggesting a potential limitation in the way
of performing current cluster analyses.9 In addition to the natural
disease variability, many factors such as therapy, lifestyle, and
comorbidities may modify the disease course. Reliability of the
results of a cluster analysis would be increased by including
clinical data from several time points of the disease follow-up into
the analysis.
Here, we used a long-term follow-up approach to construct
phenotypes of adult-onset asthma by carrying out a cluster
analysis with inclusion of variables from diagnosis to a 12-year
follow-up visit. This approach provides novel insights into the
phenotypes of asthma with prognostic signiﬁcance.METHODS
Patients and study design
The present study was part of the Seinäjoki Adult Asthma Study
(SAAS), which is a prospective, single-center (Seinäjoki Central
Hospital, Seinäjoki, Finland), 12-year follow-up study of a cohort of
consecutive white patients having new-onset asthma diagnosed at
adult age (15 years). SAAS has been registered on ClinicalTrials.gov
with ID NCT02733016. Institutional permissions (TU1114 and
LET) were obtained and the participants gave written informed
consent to the study protocol approved by the Ethics Committee of
Tampere University Hospital, Tampere, Finland (R12122). The
protocol, inclusion and exclusion criteria, and the background data of
SAAS have been published elsewhere.11 Brieﬂy, asthma was diagnosed
by a specialized respiratory physician during the period 1999 to 2002
on the basis of typical clinical symptoms and conﬁrmed by objective
lung function measurements.11,12 The main diagnostic features of
asthma in each cluster are presented in Table E1 in this article’s
Online Repository at www.jaci-inpractice.org. Smokers and patients
with comorbidities were not excluded. After diagnosis, the patients
were treated and monitored in specialized or primary care as
required. The total cohort consisted of 257 patients and 203 patients
completed the follow-up visit (mean follow-up time, 12.2 years;
range, 10.8-13.9 years). At 12-year follow-up visit, asthma status
and disease control, comorbidities, and medication were evaluated
using structured questionnaires and lung function was measured.
Data on asthma-related visits to health care and hospitalizations were
also collected from primary care, occupational health care, private
clinics, and hospitals. After excluding those with missing data,
171 patients with adult-onset asthma remained in the cohort for
cluster analysis (Figure 1).
Lung function, comorbidities, inflammatory
parameters, and other clinical measurements
Lung function was measured with a spirometer according to in-
ternational recommendations.13 The following were the lung func-
tion measurement points: (1) baseline (time of asthma diagnosis),
(2) the maximum prebronchodilator FEV1 (Pre-BD FEV1) during
the ﬁrst 2.5 years after diagnosis (Max0-2.5) (and after start of
anti-inﬂammatory therapy), and (3) 12-year follow-up.14 Detailed
information on determination of lung function, inﬂammatory pa-
rameters, and comorbidities can be found in this article’s Online
Repository at www.jaci-inpractice.org. Asthma control was assessed
according to the Global Initiative for Asthma 2010 report.15 Patients
ﬁlled out the Airways Questionnaire 20 (AQ20) at baseline visit and
AQ20 and asthma control test (ACT) questionnaires at the follow-
up visit. The AQ20 is a short and simple well-validated question-
naire to measure and quantify disturbances in the airway-speciﬁc
quality of life.16 ACT is a widely used patient self-administered
tool for identifying those with poorly controlled asthma.17
Variable selection
Input variables for the cluster analysis were selected on the basis of
factor analysis (see Table E2 in this article’s Online Repository at
www.jaci-inpractice.org). Basic and clinical variables included in
factor analysis were chosen to cover as wide a range as possible from
diagnosis to 12-year follow-up visit and are further discussed in this
article’s Online Repository at www.jaci-inpractice.org.
Cluster analysis and discriminant analysis
Cluster analysis was carried out by using a 2-step process. First,
Ward hierarchical cluster analysis was performed for preevaluation of
Years 1999-2002 
Baseline visit 
Patients with new diagnosis of asthma 
(age ≥ 15 years) were included 
n = 260 
Patients excluded 
n = 32 missing information 
on input variables of 
cluster analysis 
Years 2012-2013 
12-year follow-up visit 
n = 203 
Response rate=79 %
Patients excluded 
n = 1 consent withdrawn 
n = 2 childhood asthma 
Patients lost during follow-up 
n = 22 dead 
n = 9 could not be reached 
n = 5 significant comorbidities 
n = 18 other reasons 
Final study population 
n = 171 
Visits to 
healthcare 
Hospitalizations 
FIGURE 1. Flow chart of the study.
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using the prespeciﬁed number of clusters (5). Stepwise discriminant
analysis was performed to identify variables discriminating between
the prespeciﬁed clusters. Statistically signiﬁcant results were expected
for most of the comparisons because the objective of the cluster
analysis was to differentiate the participants into distinct phenotypes
of adult-onset asthma.
Other statistical analyses
Continuous data are expressed as mean  SD or median and
interquartile range. Group comparisons were performed by 1-way
analysis of variance with the Tukey post hoc test, the Kruskal-
Wallis test, or the chi-square test. Statistical analyses were
performed by using SPSS software, version 22 (IBM Corporation,
Armonk, NY) and MATLAB, version 8.6 (Mathworks, Natick,
Mass).RESULTS
Patients’ characteristics
Characteristics of the total cohort at baseline and follow-up are
presented in Table E3 in this article’s Online Repository at www.
jaci-inpractice.org. Patients were mostly females (58.5%) and
nonatopic (63.5%), with age at asthma onset ranging from 15 to
77 years. At diagnosis, most patients were steroid-naive. At the
12-year follow-up point, 78.9% were daily users of inhaled
corticosteroid (ICS) and 50.9% were daily users of ICS and
add-on medication.
Cluster analysis
By performing Ward hierarchical and K-means cluster ana-
lyses, 5 clusters were identiﬁed. The basic characteristics of these
clusters are shown in Figure 2. Cluster 1 was characterized by low
prevalence (10.5%) of rhinitis (nonrhinitic asthma), whereas
cluster 2 had the highest smoking history (smoking asthma).
Cluster 3 consisted mainly (98%) of women (female asthma),
and most patients in cluster 4 were obese from diagnosis to
12-year follow-up visit (obesity-related asthma). Cluster 5 mostly
included atopic patients with the earliest onset of asthma (early-
onset atopic adult asthma). Basic and clinical characteristics of
the clusters at baseline and at follow-up are presented in
Tables I-IV. There were no major differences in the maindiagnostic features between groups (see Table E1 in this article’s
Online Repository at www.jaci-inpractice.org).
Cluster 1: Nonrhinitic asthma. Cluster 1 (n ¼ 38
[22.2%]) was characterized by lack of rhinitis, male predomi-
nance (60.5%), onset of asthma at middle age, and second
highest smoking history (Figure 2). Proportion of patients with
permanent bronchial obstruction (post-BD FEV1/forced vital
capacity [FVC] <0.7) increased from 10.8% to 39.5% from
diagnosis to 12-year follow-up visit. This cluster also showed the
highest weight gain, with the proportion of obese patients
increasing from 18.4% to 39.5%. Asthma was uncontrolled in
only 5.3% of the patients, even though most (55.9%) were
treated with low-dose ICS or no daily ICS (Table I). Cluster 1
showed moderate loss of FEV1 during the follow-up and the
lowest use of health care (Figures 3 and 4). Patients had 1 co-
morbidity on average at the 12-year follow-up visit, the most
prevalent being chronic obstructive pulmonary disease (COPD)
and hypertension (Table IV).
Cluster 2: Smoking asthma. Cluster 2 was the smallest
cluster (n ¼ 19 [11.1%]) and was predominated by older males.
Almost 80% of patients had smoking history and 44.4% showed
bronchial obstruction at diagnosis and could be characterized as
having asthma-COPD overlap syndrome (ACOS).18 However,
the smoking cluster did not differ from other clusters on the basis
of diffusing capacity. The patients had poor lung function, high
symptoms, and uncontrolled asthma despite 94.7% being under
daily ICS therapy, 73.4% with moderate-to high-dose ICS, and
78.9% with long-acting b2 agonist at follow-up. Even though
lung function signiﬁcantly improved after start of therapy, the
annual decline in FEV1 was steep (78 mL on average) from the
maximum point of lung function to the 12-year follow-up visit
(Figure 4; Table II). This was the only group with no decrease in
blood eosinophils or symptoms from diagnosis to follow-up
(Figure 4). The patients had 3 comorbidities on average
(Table IV) and frequent health care use (Figure 3). Of the pa-
tients, 36.8% had been hospitalized for asthma (Figure 3, B) and
this cluster accounted for 35.8% of all hospital treatment
periods.
Cluster 3: Female asthma. This group was the largest (n ¼
50 [29.2%]) and consisted of women with a wide range in the
age of asthma onset. Cluster 3 contained more (44%) patients
with normal weight (body mass index <25) compared with other
clusters and showed the lowest smoking history. Forty percent
reported being symptomatic already during childhood even
though they were not diagnosed as having asthma. Pre-BD FEV1
was normal (>80% predicted) in 78% at diagnosis and in 90%
at follow-up, and the annual decline in FEV1 was the lowest (31
mL). Blood eosinophils were the second highest and the AQ20
symptom score was at a rather moderate level of 6 out of 20 at
diagnosis, and both reduced during the follow-up (Figure 4).
Even though lung function measured by spirometry and
inﬂammation were within normal range and 78% were under-
going ICS treatment at the 12-year follow-up visit, 64% of the
patients were partially controlled or uncontrolled and health care
use was relatively high (Table I; Figure 3). Female cluster
accounted for 29.0% of all asthma-related visits.
Cluster 4: Obesity-related asthma. This cluster (n ¼ 25
[14.6%]) mostly contained nonatopic females with the oldest age
FIGURE 2. Basic characteristics of clusters. In A-F, C1 to C5 refer to the cluster numbers. Overall P values are shown. In B and F, the red
lines shown are means. In D, means are shown. BMI, Body mass index; DG, diagnosis.
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to the 12-year follow-up point without gaining more weight
during this time. The patients were multimorbid at follow-up
(Table IV), with the most prevalent comorbidities being hyper-
tension, diabetes, and psychiatric diseases. Asthma was uncon-
trolled in 48% of the patients at follow-up even though 92%
were undergoing ICS treatment, 50% used high-dose ICS, and
72% were on add-on medication (Table I). At diagnosis, 44%
showed pre-BD FEV1 of more than 80% predicted. Lung
function improved on start of therapy and remained relatively
stable throughout follow-up (Figure 4, A). Respiratory symp-
toms, use of oral steroids, and health care use were all at high
levels (Figures 3 and 4).Cluster 5: Early-onset atopic adult asthma. This
group was the second largest (n ¼ 39 [22.8%]) and consisted of
the youngest patients with mean age of asthma onset at 33  11
years. Almost half had suffered from respiratory symptoms
during childhood, 59% were atopic, and 90% had nonallergic
or allergic rhinitis (Table I). Of this cluster, 59% showed pre-
BD FEV1 of more than 80% at diagnosis and 84% could be
reversed to FEV1 of more than 80% predicted by BD.
Reversibility was in general the highest. Lung function initially
showed a good response to steroids, even though the loss of
lung function after the maximum point was also the second
steepest. At diagnosis, these patients showed the highest blood
eosinophils (Table III), which reduced until the 12-year follow-
up visit (Figure 4). Asthma was controlled in 56% of the
subjects and use of medication was the lowest, because 56%
were using low-dose ICS or no medication and only 17.9%
were treated by long-acting b2 agonist (Table I). Use of steroid
bursts was infrequent and use of health care was among the
lowest (Figure 3).Validation
For validation, we carried out K-means algorithm 10 times by
the leave-one-out method to ensure stability and repeatability of
the model. This method showed 94.4% repeatability.
Discriminant analysis
By using a stepwise method of discriminant analysis, 12 out of
17 variables were found to signiﬁcantly discriminate between the
clusters: the diagnostic variables were post-BD FEV1/FVC, FEV1
reversibility, and maximal change in FEV1 (from diagnosis to
Max0-2.5), whereas the follow-up variables included rhinitis,
number of drugs in use to treat comorbidities, pre-BD FEV1,
pack-years, body mass index, limitation of activities (none/any),
and basic variables of sex, age at asthma onset, and symptoms of
asthma for less than 16 years, of which rhinitis, post-BD FEV1/
FVC, number of drugs in use to treat comorbidities, and sex
were found to be the strongest discriminating variables. Duration
of symptoms before diagnosis, blood eosinophils and neutro-
phils, reversibility at follow-up, and ACT score were not found as
statistically signiﬁcant discriminants. The percentage of correct
classiﬁcation on the basis of the 12 discriminating variables was
94.7% (data not shown).DISCUSSION
In this study, we identiﬁed phenotypes of adult-onset asthma
by using longitudinal data and basic and clinical variables ranging
from the diagnostic phase to the 12-year follow-up visit. Our
cohort included smokers and patients with comorbidities. The
following 5 phenotypes were identiﬁed: (1) nonrhinitic
controlled to partially controlled asthma with low use of medi-
cation and health care; (2) smoking asthma or ACOS with poor
lung function, high symptoms, and high use of medication and
health care; (3) female asthma with normal clinical parameters
TABLE I. General features of clusters
Features
Cluster 1:
nonrhinitic (n [ 38)
Cluster 2:
smoking (n [ 19)
Cluster 3:
female (n [ 50)
Cluster 4:
obese (n [ 25)
Cluster 5:
atopic (n [ 39)
P value
between
clusters
P value
between
clusters
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Demographic characteristics and anthopometrics
Females, n (%) 15 (39.5) 2 (10.5)* 49 (98)† 16 (64) 18 (46.2) <.001
Age (y), mean  SD 50  12 63  12 55  9 66  9 43  12† 55  12† 57  8 69  8 33  11† 45  11† <.001 <.001
BMI (kg/m2), mean 
SD
28.1  5.5z 29.9  6.5 27.8  4.0 28.1  4.9 26.3  4.3 27.1  4.8 32.7  5.2† 32.8  5.3zxjj 24.9  3.5 26.8  3.9 <.001 <.001
Obese (BMI > 30), n (%) 7 (18.4) 15 (39.5) 8 (42.1)z 7 (36.8) 7 (14.0) 13 (26.0) 17 (68.0)zjj{ 18 (72.0)† 4 (10.3) 9 (23.1) <.001 .001
Smokers, n (%) 20 (52.6) 20 (52.6) 15 (78.9)jj 15 (78.9)jj 17 (34) 18 (36) 11 (44) 11 (44) 19 (48.7) 21 (53.8) .020 .027
Current smoker, n (%) 7 (18.4) 7 (18.4) 5 (26.3) 3 (15.8) 5 (10) 8 (16) 4 (16) 0 9 (23.1) 8 (20.5) .425 .225
Pack-years of smokers,
median (IQR)
17 (12-23)jj 19 (15-29)zjj 29 (14-34)*zjj 33 (15-38)zjj 5 (2-10) 6 (2-18) 15 (10-20) 15 (10-25) 4 (3-7) 6 (3-15) <.001 <.001
Symptoms of asthma
<16 y, n (%)
0 1 (5.3) 20 (40.0)*{ 1 (4.0) 19 (48.7)*x{ <.001
Symptoms of asthma
before diagnosis (mo),
median (IQR)
18 (9-60) 24 (11-36) 12 (9-36) 24 (24-60)zjj 12 (8-24) .008
Atopic, n (%) 9 (27.3) ND 5 (31.3) ND 19 (40.4) ND 2 (9.1) ND 22 (57.9)* ND .003 ND
No. of positive SPT,
median (IQR)
0 (0-1) ND 0 (0-2) ND 0 (0-2)* ND 0 (0-0) ND 1.5 (0-3)*x{ ND .001 ND
Rhinitis, n (%) ND 4 (10.5)† ND 14 (73.7) ND 44 (88) ND 24 (96) ND 35 (89.7) ND <.001
Asthma control and quality of life
AQ20 score, median
(IQR)
5 (3-7) 2 (1-4) 8 (5-10) 8 (5-11)zjj{ 6 (4-10) 4 (2-6) 10 (7-13)zjj{ 7 (4-9)z{ 4 (2-9) 2 (1-5) <.001 <.001
ACT score, median
(IQR)
ND 23 (21-24) ND 20 (13-21)zjj{ ND 22 (19-24) ND 19 (15-22)z{ ND 23 (21-25) ND <.001
ACT score <20, n (%) ND 5 (13.2) ND 9 (47.4)z{ ND 13 (26.0) ND 15 (60.0)zjj{ ND 5 (12.8) ND <.001
Controlled, n (%) ND 16 (42.1) ND 2 (10.5) ND 18 (36) ND 4 (16) ND 22 (56.4)*x ND <.001
Partly controlled, n (%) ND 20 (52.6)x ND 1 (5.3) ND 21 (42)x ND 9 (36) ND 11 (28.2) ND .007
Uncontrolled, n (%) ND 2 (5.3) ND 16 (84.2)zjj{ ND 11 (22){ ND 12 (48)z{ ND 6 (15.4) ND <.001
Exacerbations
Oral steroids, n (%)# 2 (5.4) 4 (21.1) 6 (12.2) 7 (29.2) 2 (5.1) .026
Treatment
Daily ICS user, n (%)** 1 (2.6) 27 (71.1) 1 (5.3) 18 (94.7) 6 (12.2) 39 (78) 2 (8.0) 23 (92) 2 (5.1) 28 (71.8) .479 .089
ICS dose,†† median
(IQR)
900 (800-1600) 800 (400-1000) 800 (700-1600) 900 (700-1400) 800 (400-1000) 800 (575-1000) 1000 (800-1400) 1000 (475-1525) 800 (800-1600) 800 (400-800) .220 .163
Low/none ICS dose, n (%) ND 19 (55.9) ND 4 (26.7) ND 18 (40) ND 6 (30) ND 20 (55.6) ND .109
Medium ICS dose, n (%) ND 7 (20.6) ND 4 (26.7) ND 11 (24.4) ND 4 (20) ND 11 (30.6) ND .871
(continued)
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972 ILMARINEN ETALbut relatively high use of health care; (4) obesity-related asthma
with comorbidities, high symptoms, and high use of medication
and health care; and (5) atopic well-controlled asthma with onset
earlier in adulthood. Instead of characterizing phenotypes in one
point of disease, we provide phenotypes based on 12-year
follow-up data.
Our results show both similarities to and differences from those
of previous cluster analyses based on cross-sectional data with
mixed duration of asthma. Most previous analyses have excluded
smokers or heavy smokers and only few have identiﬁed smoking
asthma.6,19 Cluster A in the Cohort for Reality and Evolution of
Adult Asthma in Korea (COREA) study6 resembled our smoking
cluster in many respects. However, in our study, the smoking
cluster showed an annual decline in FEV1 that was the steepest of
all groups in contrast to the results of the COREA smoking cluster
in 1-year follow-up. Many negative outcomes previously associated
with smoking asthma were evident in our smoking cluster,
including lower asthma-related quality of life (based on AQ20
score), frequent health care use, and severe/uncontrolled
asthma.20-22 Even though the patients in the smoking cluster
typically show irreversible airﬂow limitation and comorbidity
proﬁles resembling that of COPD, normal average diffusing ca-
pacity in each cluster suggests that the main diagnosis is asthma
and not emphysema. In addition, the diagnosis of asthma was
made by a respiratory specialist and each patient fulﬁlled the
diagnostic criteria of asthma including objective lung function
measurements showing bronchial variability. This smoking group,
although being the smallest one, was responsible for more than a
third of all asthma-related hospitalizations, highlighting the sig-
niﬁcance of this group to health care costs. Obviously, much ef-
forts should be focused on advising patients to stop smoking as
early as possible, even before onset of asthma and before asthma
turns from a milder form to difﬁcult-to-treat smoking asthma with
high burden for both individual and health care.
Obesity-related female-predominant asthma is a cluster iden-
tiﬁed in our study as well as in some previous studies,2,5,7,10 and
our results add by providing data on prognosis of the long-term
obesity. Our results on this cluster support previous ﬁndings
indicating frequent symptoms and exacerbations, high use of
health care, high medication, and a nonatopic, noneosinophilic
disease characteristic. This cluster is also prone to create a high
burden to health care, as evidenced by the most frequent use of
oral corticosteroids and of health care services. To further add on
previous studies, we found the highest number of comorbidities
in the obese cluster and especially a high prevalence of psychiatric
comorbidity (40%). Consistently, in a previous study, the
highest depression score was shown in the late-onset obese cluster
in a cohort of severe asthma.7 However, interaction between
obesity, psychiatric diseases, and asthma requires further
studies.23,24 Recently, we showed that multimorbidity is associ-
ated with increased symptoms of asthma, which may be partly
related to systemic inﬂammation in these patients.25 Systemic
inﬂammation has been associated with high steroid dose in the
treatment of adult-onset asthma.25 Therefore, multimorbidity
and systemic inﬂammation may be relevant in turning
asthma into symptomatic and steroid-resistant in obese patients.
However, weight loss has resulted in improved symptoms, lung
function, asthma control, and health status,23 suggesting that it
would beneﬁt this subgroup.
In addition to the obesity-related female-predominant group,
we identiﬁed a nonobese cluster of females with good lung
TABLE II. Lung function of clusters (mean  SD)
Characteristic
Cluster 1:
nonrhinitic (n [ 38)
Cluster 2:
smoking (n [ 19)
Cluster 3:
female (n [ 50)
Cluster 4:
obese (n [ 25)
Cluster 5:
atopic (n [ 39)
P value
between
clusters
P value
between
clusters
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Lung function
Pre-BD FEV1, %ref 82  15 85  14* 53  18† 63  19† 90  12 96  13 78  13* 79  16* 81  14* 86  12* <.001 <.001
Post-BD FEV1, %ref 86  16 89  14* 60  18† 67  20† 94  13 98  13 83  14* 81  16*z 92  12 92  12 <.001 <.001
Pre-BD FVC, %ref 90  16 97  14 73  17*zx 90  15* 95  12 103  14 84  13* 88  14* 93  15 98  14 <.001 <.001
Post-BD FVC, %ref 92  16 100  16 81  16*z 93  14 96  13 103  14 86  12*z 90  14* 97  13 99  14 <.001 .007
Pre-BD FEV1/FVC,
%ref
0.75  0.08* 0.71  0.08* 0.57  0.11† 0.57  13† 0.80  0.07 0.76  0.05 0.76  0.06 0.72  0.10 0.74  0.10* 0.72  0.07 <.001 <.001
Post-BD FEV1/FVC,
%ref
0.77  0.07* 0.72  0.08* 0.58  0.12† 0.58  0.14† 0.83  0.07 0.78  0.05 0.78  0.08 0.72  0.10* 0.81  0.08 0.76  0.07 <.001 <.001
FEV1 reversibility (mL) 166  137 134  147* 267  251 142  172* 139  142 47  69 144  211 62  104 407  204*xjj 195 143*xjj <.001 <.001
FEV1 reversibility
(% change)
5.6  5.3 4.8  5.2* 15.0  16.4*zxjj 6.8  7.7* 5.9  7.8 1.8  2.8 6.2  8.8 3.2  5.3 14.2  13.6*xjj 6.6  5.6* <.001 <.001
Diffusing capacity
DLCO/VA (%ref) 104  17 100  15 94  21 88  28 100  20 95  14 99  18 93  13 107  16 97  14 .155 .107
Annual change in lung
function from
Max0-2.5 to
follow-up{
DFEV1 (mL/y) 49  32* 78  54* 31  24 46  30 59  40* <.001
DFVC (mL/y) 37  32 48  63 24  31 40  39 38  49 .173
Maximal change in FEV1
(D from diagnosis to
Max0-2.5)
DFEV1 (mL#) 266  365 972  899*zxjj 161  252 184  239 561  459*xjj <.001
DLCO, Diffusing capacity of the lung for carbon monoxide; ref, reference; VA, alveolar volume.
*P < .05 vs cluster 3 at corresponding time point (baseline or follow-up).
†P < .05 to all other clusters at corresponding time point (baseline or follow-up).
zP < .05 vs cluster 5 at corresponding time point (baseline or follow-up).
xP < .05 vs cluster 1 at corresponding time point (baseline or follow-up).
jjP < .05 vs cluster 4 at corresponding time point (baseline or follow-up). Paired comparison between baseline and follow-up is not shown.
{Annual change in FEV1 or FVC from point of maximal lung function within 2.5 y after start of therapy to the 12-y follow-up visit.
#DFEV1 when deducting pre-BD FEV1 value at diagnosis from pre-BD FEV1 value at point of maximal lung function within 2.5 y from start of therapy; reﬂects early response to treatment.
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974 ILMARINEN ETALfunction and a wide range in the age of asthma onset. The
previously deﬁned clusters “least severe asthma with normal lung
function,” “middle-age onset, female-dominant,” and “late-onset
mild asthma”6,7,19 show resemblance to our female cluster,
including predominance of nonobese females, normal lung
function,6,7,19 and stable lung function in the short follow-
ups.6,7 Low smoking history, low body mass index, low count of
comorbidities, and high eosinophils at diagnosis may have
affected the good overall prognosis of the female cluster. How-
ever, the health care use was relatively high in this group given
that many clinical parameters were within normal range. This
may be explained by females’ stronger perception of symptoms
and lower threshold to contact health care when compared with
males.26 In addition, female patients with similar severity of
asthma as the corresponding male patients have shown better
lung function but worse asthma-related quality of life.26 In this
cluster, lung function based on spirometry was more stable when
compared with lung function in other groups, but peak expira-
tory ﬂow follow-up might have shown variable obstruction and
disease activity. In addition, whether parameters such as blood
eosinophils or airway hyperresponsiveness better correlate to
disease activity and symptoms remains unclear. In the female
cluster, roughly half of the patients were at fertile age, and the
other half at menopausal or postmenopausal age at asthma onset,
suggesting that no uniform sex hormoneerelated mechanism
explains the pathophysiology of asthma in this cluster. However,
hormonal aspects probably play a signiﬁcant role in the patho-
genesis and course of the disease,26-31 even though the mecha-
nisms are likely multifactorial. Presence of symptoms at
childhood in 40% of the patients also suggests the involvement
of TH2-related mechanisms and some overlap with cluster 5.
Similar to previous ﬁndings,32 most patients in our study had
a coexisting allergic or nonallergic rhinitis. However, we also
identiﬁed a nonatopic mild to moderate male-predominant
asthma without rhinitis, which to our knowledge has not been
reported previously. Despite the second highest smoking history,
40% prevalence of permanent bronchial obstruction, and obesity
at follow-up, these patients had signiﬁcantly better prognosis
when compared with those in clusters 2 and 4. Rhinitis has been
associated with more severe asthma,32,33 suggesting that lack of
rhinitis is a signiﬁcant determinant associated with the favorable
prognosis in this group. Male predominance, moderate smoking
history, and the highest weight gain suggest that pathophysio-
logical mechanisms in this cluster are related to those features.
Asthma in obese men has been reported to be less often severe
when compared with that in obese women26 and obesity-related
asthma may have important sex-speciﬁc differences concerning
the mediators of the disease.34,35 For example, in a recent study,
no similar difference existed in systemic inﬂammation between
nonobese and obese males as seen in females.35 Lower level of
systemic inﬂammation could also contribute to lesser number of
comorbidities and better prognosis of asthma. Further studies are
needed to evaluate the pathophysiological mechanisms in this
cluster.
Cluster 5 in our study ﬁts well with the previous ﬁndings of
the important role of age of onset in deﬁning the phenotype.1,3
Atopy, childhood symptoms, earliest onset of asthma, good
steroid-responsiveness, and large FEV1 reversibility support the
conclusion that this cluster represents the traditional early-onset
asthma but starting at early adulthood. In addition, the good
prognosis strengthens the view.36 A corresponding adult-onset
TABLE IV. Comorbidities of clusters
Comorbidity
Cluster 1:
nonrhinitic (n [ 38)
Cluster 2:
smoking (n [ 19)
Cluster 3:
female (n [ 50)
Cluster 4:
obese (n [ 25)
Cluster 5:
atopic (n [ 39)
P value
between clusters
P value
between
clusters
Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
Hypertension, n (%) 4 (10.5) 9 (23.7) 4 (21.1) 13 (68.4)*†z 3 (6.0) 7 (14.0) 12 (48.0)*†z 19 (76.0)*†z 2 (5.1) 6 (15.4) <.001 <.001
Diabetes, n (%) 0 4 (10.5) 0 7 (36.8)†z 0 3 (6.0) 3 (12.0) 11 (44.0)*†z 0 2 (5.1) <.001 <.001
Coronary heart
disease, n (%)
1 (2.6) 5 (26.3)†z 0 2 (8.0) 0 <.001 <.001
COPD, n (%) 2 (5.4) 9 (23.7)† 8 (44.4)x 10 (52.6)†zjj 0 1 (2.0) 0 2 (8.0) 1 (2.6) 3 (7.7) <.001 <.001
Any psychiatric
disease, n (%)
ND 3 (7.9) ND 1 (5.3) ND 5 (10) ND 10 (40)*†z ND 3 (7.7) ND .001
Depression, n (%) ND 1 (2.6) ND 1 (5.3) ND 3 (6.0) ND 7 (28)* ND 2 (5.1) ND .004
Painful condition,
n (%)
ND 3 (7.9) ND 2 (10.5) ND 2 (4) ND 5 (20) ND 1 (2.6) ND .090
Treated dyspepsia,
n (%)
ND 1 (2.6) ND 2 (10.5) ND 4 (8) ND 6 (24) ND 1 (2.6) ND .020
Total no. of
comorbidities,
median (IQR)
ND 1 (0-2)z ND 3 (1-4)*†z ND 0.5 (0-1) ND 3 (2.5-4)*†z ND 0 (0-1) ND <.001
No. of drugs{, median
(IQR)
ND 1 (0-3) ND 3 (2-9)*†z ND 1 (0-2) ND 6 (4-7)*†z ND 0 (0-2) ND <.001
IQR, Interquartile range; ND, not determined.
*P < .05 vs cluster 1 at corresponding time point (baseline or follow-up).
†P < .05 vs cluster 3 at corresponding time point (baseline or follow-up).
zP < .05 vs cluster 5 at corresponding time point (baseline or follow-up).
xP < .05 vs all clusters at corresponding time point (baseline or follow-up).
jjP < .05 vs cluster 4 at corresponding time point (baseline or follow-up). Paired comparison between baseline and follow-up is not shown.
{Number of drugs in use to treat comorbidities.
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FIGURE 4. Longitudinal changes in lung function, blood eosinophils, and symptoms (AQ20) in 5 clusters of adult-onset asthma. In A: *P <
.05, **P<.01, and ***P<.001, at left side DFEV1 from diagnosis to Max0-2.5, and at right side DFEV1 fromMax0-2.5 to 12-y follow-up visit
within the cluster. In B and C: *P < .05, **P < .01, and ***P < .001 of DFEV1 from diagnosis to follow-up visit within each cluster.
FIGURE 3. Asthma-related use of health care and use of oral steroids during the follow-up period. In A, shown is the number of asthma-
related visits to health care during the 12-year follow-up period. The red lines shown are means. In B, shown is the proportion of patients
with at least one hospitalization during the 12-year follow-up period. In C, shown is self-reported oral steroid use within two years before
the 12-year follow-up visit. In A-C, C1-C5 refers to the cluster number.
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have recognized childhood-onset atopic asthma.5,7,10 A rather
high annual lung function decline was seen after the reach of
maximum point but this may be related to lung capacity because
higher reversibility and higher maximal FEV1 enable higher
decline in lung function. More than 70% of the patients were
daily users of ICS and most were well controlled at follow-up,
suggesting good compliance to treatment. Poor compliance was
suspected to explain poorer outcome of early-onset asthma in aprevious study.10 Because increased age has been associated with
increased risk of severe asthma,37 younger age may also signiﬁ-
cantly contribute to the good prognosis in this group.
In 2 previous studies, an eosinophilic inﬂammation-
predominant late-onset cluster was identiﬁed in contrast to our
ﬁndings. One reason for the absence of this group may be the
absence of sputum eosinophil measurements in our study and its
absence as an input variable of cluster analysis, which is
considered as a limitation of our study.2,10 However, use of
TABLE V. Summary of phenotypes with their basic diagnostic characteristics, prognoses, and speculated drivers
Features Cluster 1: nonrhinitic Cluster 2: smoking Cluster 3: female
Cluster 4:
obesity-related
Cluster 5:
early-onset atopic
Basic characteristics Males 40-60 y (moderate
smoking history)
and lack of rhinitis,
weight gain
Older males with
heavy smoking
history
Females 20-60 y,
normal
overweight
Older obese females Younger atopic
adults with high
eosinophils, may
have symptoms
in childhood
Pre-BD FEV1
Baseline >80% <60%, obstruction >90% <80% >80%
Follow-up >80% <70%, obstruction >90% <80% >80%
Symptoms
Baseline Moderate High Moderate High Low
Follow-up Low High Low-moderate High Low
Eosinophilic
inﬂammation
Baseline Moderate Moderate High Moderate High
Follow-up Low Moderate-high Low Low Moderate
Asthma control
at follow-up
Partially Uncontrolled Partially Uncontrolled Controlled by low
steroid dose
Comorbidities May develop HTN, COPD Has/may develop HTN,
COPD, CHD, DM
Rarely Has/may develop HTN,
DM, PSY, CHD
Rarely
Health care utilization Low High Moderate High Low
Driver related to? Smoking, obesity Smoking Sex hormones,
TH2 mechanism
Obesity, systemic
inﬂammation
TH2 mechanism
CHD, Coronary heart disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; PSY, psychiatric disease.
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ILMARINEN ETAL 977blood eosinophils and fractional exhaled nitric oxide is supported
by a recent study showing that airway eosinophilia in adult pa-
tients can be reliably and accurately identiﬁed by blood eosino-
phils and fractional exhaled nitric oxide instead of induced
sputum, and the accuracy is similar in different phenotypes.38
Furthermore, in the previous study,2 there was speculation on
nonadherence, which might lead to persistent eosinophilia, and
on overrepresentation of severe asthma because of the recruit-
ment process. Previous studies with patients with adult-onset
asthma have recognized larger groups of late-onset benign
asthma,2,6,10 but our study gives a more detailed analysis of the
population with mild to moderate asthma by separating it into 3
clusters (female, nonrhinitic, and atopic). Our approach reveals
speciﬁc features of the prognoses of these groups that may more
closely reﬂect the underlying pathobiology.
Our study has many strengths. Inclusion of diagnostic data
gives the clinician more accurate tools to evaluate the phenotype
of asthma at early phase, which helps to plan future therapy and
follow-up. Wide inclusion of patients, including heavy smokers,
multimorbid patients, and all severities of asthma makes our
analysis clinically signiﬁcant and close to real life. Limitations to
this study also exist. Subjectivity cannot be avoided because
variables included in factor or cluster analysis had to be selected
as well as the method of cluster analysis. However, every effort
was made to avoid bias due to subjectivity, for example, wide
inclusion of clinical and basic variables to factor analysis and
predominantly factor analysisebased selection of variables to
cluster analysis. One can also argue about the small size of the
cohort, being, however, comparable with many previous
studies.2,10
Altogether, we identiﬁed 5 clusters of adult-onset asthma with
clinical relevance and clear basic characteristics and with 12-year
prognosis (Table V). To our knowledge, this is the ﬁrst studyusing long-term data in the construction of clusters, and is the
ﬁrst to succeed in identifying clusters with different disease
prognoses. These results can be used in clinics to predict out-
comes of patients with adult-onset asthma and to plan medica-
tion and follow-up. In addition, our results may aid in the
development of personalized therapy. Even though this study
concentrated on deﬁning the clinical phenotypes, the results are
encouraging when considering the possible pathobiological
similarities within each cluster, being an important goal in future
studies.
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Methods
Lung function measurement, inflammatory parame-
ters, and other clinical measures. Lung function mea-
surements were performed with a spirometer (Vmax Encore 22,
Viasys Healthcare, Palm Springs, Calif) that was calibrated daily.
Post-BD measurements were taken 15 minutes after inhalation
of salbutamol (400 mg). Finnish reference values were used.E1
Fractional exhaled nitric oxide was measured with a portable
rapid-response chemiluminescent analyzer according to the
American Thoracic Society standardsE2 (ﬂow rate, 50 mL/s;
NIOX System, Aerocrine, Sweden). Venous blood was collected
and white blood cell differential counts were determined. Total
IgE levels were measured by using ImmunoCAP (Thermo
Scientiﬁc, Uppsala, Sweden). Laboratory assays were performed
in an accredited laboratory (SFS-EN ISO/IEC 17025:2005 and
ISO 15189:2007) of Seinäjoki Central Hospital. Patients
completed the AQ20 and the ACT.
Comorbidities. Comorbidities were self-reported or based on
self-reported medication, and their deﬁnitions and classiﬁcations
were based on previous studies.E3,E4 Unclear cases were
conﬁrmed from patient records. Conditions included as
comorbidities were hypertension, depression, painful condition
(daily use of analgesic medication), coronary heart disease,
treated dyspepsia (daily medication), diabetes, thyroid disorders,
rheumatoid arthritis, and other inﬂammatory polyarthropathies
and systematic connective disorders, anxiety and other stress-
related and somatoform disorders, irritable bowel syndrome,
cancer, treated constipation, stroke and transient ischemic attack,
chronic kidney disease, diverticular disease of the intestine, atrial
ﬁbrillation and other cardiac arrhythmias, peripheral vascular
disease, heart failure, prostate disorders, glaucoma, epilepsy, de-
mentia, schizophrenia/nonorganic psychosis or bipolar disorder,
psoriasis, inﬂammatory bowel disease, migraine, bronchiectasis,
Parkinson disease, multiple sclerosis, viral hepatitis, and chronic
liver disease. Alcohol problems, anorexia or bulimia, misuse ofpsychoactive substance, hearing loss, and blindness or low vision
were left out because the presence of these conditions could not
be assessed on the basis of patients’ self-reports.Variable selection for factor analysis and cluster
analysis. Fifty-one variables from the following 3 time points
were included in factor analysis: diagnosis, time of Max0-2.5, and
12-year follow-up visit. Variables included were related to lung
function, reversibility, symptoms (AQ20 and ACT scores,
Global Initiative for Asthma control assessment, duration of
respiratory symptoms before diagnosis of asthma, and childhood
respiratory symptoms), basic variables (body mass index, Dbody
mass index, age of asthma onset [at asthma diagnosis], sex, and
smoking), comorbidities, atopy and rhinitis, inﬂammatory
parameters (fractional exhaled nitric oxide, blood eosinophils,
blood neutrophils, and total IgE), diffusing capacity, work-
related asthma (deﬁned by the question “Does your asthma
aggravate during working day?”), aspirin-sensitive asthma, and
ACOS. Use of medication (ICS dose and asthma medication)
and health care use were included as composite variables. The
composite variable constructed on the basis of the use of asthma
medication was the following: 1 ¼ only short-acting b2 agonist
when needed, 2 ¼ daily ICS, 3 ¼ daily ICS and one add-on
drug, 4 ¼ daily ICS and more than 1 add-on drug, and 5 ¼
daily ICS and oral steroid and/or omalizumab. Use of the health
care composite variable was scaled on the basis of frequency of
visits to the emergency department, oral corticosteroid courses,
or absence from school or work (at least 1 of these): 1 ¼ none,
2 ¼ less than once a year, 3 ¼ once a year, and 4 ¼ more than
once a year.
When choosing variables for cluster analysis, the variable with
the highest loading was selected from each factor with an
eigenvalue higher than 1.2 with few exceptions (Table E2).
Logarithmic transformations were carried out for continuous
variables when applicable. Categorical variables were converted
into binary (0/1) variables. All variables were converted into
z scores for cluster analysis.
TABLE E1. Diagnostic criteria fulfilled by each cluster*
Diagnostic criteria fulfilled Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P value
Positive BD effect on FEV1 (15% and 200
mL) at least in 1 spirometric measurement,
n (%)
7 (18.4) 8 (42.1) 10 (20.0) 7 (28.0) 17 (43.6) .045
If not
Diurnal variability (20%) or repeated
reversibility (15%/60 L/min) in PEF
follow-up, n (%)
25 (65.8) 9 (47.4) 35 (70.0) 16 (64.0) 18 (46.2) .127
If not
Variable bronchial obstruction shown in
exercise, allergen exposure, or as a steroid
treatment response, n (%)
6 (15.8) 2 (10.5) 5 (10.0) 2 (8.0) 4 (10.3) .881
Total, n (%) 38 (100) 19 (100) 50 (100) 25 (100) 39 (100)
PEF, Peak expiratory ﬂow.
*Practically all patients underwent 1 or more spirometric evaluations and a 2-wk PEF follow-up. Other tests were performed if considered necessary. Only the major diagnostic
feature per patient is shown using a hierarchical evaluation in which positive BD response on FEV1 was considered ﬁrst, if negative, and then PEF changes were considered, and
if negative, the other tests were considered.
TABLE E2. Identified factors 1e15 in factor analysis (factor names are representative of pattern of loading)
Factors Variable with highest loading
Variable selected for cluster analysis if other than
variable with highest loading
1. Lung function Pre-BD FVC at follow-up Pre-BD FEV1 at follow-up*
2. Obstruction Post-BD FEV1/FVC at diagnosis
3. Smoking Smoking status at diagnosis (current/ex/never) Pack-years at follow-up†
4. Symptoms of asthma ACT score at follow-up
5. Age and comorbidities Number of other than asthma/allergy-related drugs in
use at follow-up
6. FEV1 reversibility at follow-up FEV1 reversibility at follow-up
7. FEV1 reversibility at diagnosis FEV1 reversibility at diagnosis
8. Obesity BMI at follow-up
9. Maximal response to treatment Maximal response in FEV1 (from diagnosis
to Max0-2.5)
10. Work-related asthma “Does your asthma aggravate during working day?”
at follow-up (yes/no)
GINA: Limitation of activities (none/any)z
11. Neutrophilic inﬂammation Blood neutrophils at follow-up
12. Symptoms of asthma <16 y “Did you have respiratory symptoms suggesting
asthma during childhood (<16 y) even though
asthma had not been diagnosed?” (yes/no)
13. Rhinitis and atopy Rhinitis at follow-up (yes/no)
14. Eosinophilic inﬂammation FENO at follow-up Blood eosinophils at follow-upz
15. Symptoms of asthma before
diagnosis
Duration of respiratory symptoms before diagnosis
Outside factor analysis Age at asthma onsetx
Outside factor analysis Sexx
BMI, Body mass index; FENO, fractional exhaled nitric oxide; GINA, Global Initiative for Asthma.
*Factor included many variables with close to similar loading, selected because of clinical aspects.
†Selected because of technical aspects.
zVariable with the second highest loading was selected because of missing values in the variable with the highest loading.
xIncluded as basic variables.
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TABLE E3. Patient characteristics of the study cohort (n ¼ 171) at baseline and follow-up visit
Characteristic At diagnosis At follow-up P value
Females, n (%) 100 (58.5) 100 (58.5)
Age (y), mean  SD 45.7  13.7 58.0  13.7
BMI, median (IQR) 26.9 (23.8-30.0) 28.1 (24.3-31.3) <.001
Current/ex-smokers, n (%) 82 (48.0) 85 (49.7) .250
Pack-years, median (IQR) 11 (4-20) 15 (5-27) <.001
Uncontrolled asthma, n (%) ND 47 (27.5)
Atopic, n (%) 57 (36.5) ND
Rhinitis, n (%) ND 121 (70.8)
Blood eosinophils (109/L), median (IQR) 0.30 (0.18-0.42) 0.17 (0.10-0.27) <.001
Daily ICS users, n (%) 12 (7.1) 135 (78.9) <.001
ICS starting/daily dose (mg budesonide
equivalents), median (IQR)
800 (800-1000) 800 (400-1000) <.001
Pre-BD FEV1 (% predicted), mean  SD 80  18 85  17 <.001
Post-BD FEV1/FVC (ratio), median (IQR) 0.79 (0.74-0.83) 0.75 (0.69-0.80) <.001
AQ20 (no. of YES), median (IQR) 6 (4-10) 4 (1-7) <.001
ACT score, median (IQR) ND 22 (19-24)
BMI, Body mass index; ND, not determined.
Note. Statistical analyses were performed by paired-samples t test, related-samples Wilcoxon signed rank test, or McNemar test.
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